Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;6(1):55-60.
doi: 10.1007/s13730-016-0244-z. Epub 2016 Nov 21.

A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant

Affiliations

A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant

Fumiaki Obata et al. CEN Case Rep. 2017 May.

Abstract

Mixed cryoglobulinemic syndrome, which is a systemic vasculitis characterized by the immune complex deposition in small- and medium-sized arteries and most often due to chronic hepatitis C virus (HCV) infection, sometimes clinically manifests as refractory glomerulonephritis or nephritic syndrome. Patients with mixed cryoglobulinemic nephropathy who have a rapidly progressive glomerulonephritis should receive immunosuppressive therapy. After disease stabilization, patients should receive concurrent therapy for the underlying HCV infection. The standard therapy of a chronic HCV infection is IFN monotherapy or IFN combined with ribavirin; however, after the introduction of direct-acting antivirals (DAAs), the standard therapy for patients with HCV genotype 1 has dramatically changed. We report a case of HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) successfully treated by daclatasvir and asunaprevir, which are IFN-free DAAs for HCV, in combination with angiotensin II receptor blocker without immunosuppressive therapy. The patient developed severe nephrotic syndrome with progressive kidney dysfunction. Blood examination revealed a high copy number of HCV-RNA (6.4 log IU/mL, type 1), cryoglobulinemia, paraproteinemia of IgM-κ, and hypocomplementemia. Histological analysis showed MPGN type 1. These findings were compatible with those observed in HCV-associated cryoglobulinemic MPGN. This case offers original evidence for the application of newer generation of IFN-free DAAs in the treatment of HCV-associated cryoglobulinemic nephropathy.

Keywords: Cryoglobulinemic membranoproliferative glomerulonephritis; Hepatitis C virus; Interferon-free direct-acting antiviral agents.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors have declared that no conflict of interest exists.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB Approval Number 680-1) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Figures

Fig. 1
Fig. 1
Pathological findings. Pathological findings show the characteristic features of an MPGN type 1. Mesangial expansion with lobular formations (a), mesangial interposition (arrow in b), and double-contour appearance of the capillary wall (arrow head in b) in glomeruli were observed by PASM-HE stain. Electron micrograph showed subendothelial electron-dense deposits (arrow in c and d) and expansion of subendothelial space (arrowhead in f). High magnification picture d and f are square in c and e, respectively. Immunofluorescence showed segmental deposits of IgG, IgM, C3, and κ along the glomerular capillary walls
Fig. 2
Fig. 2
Clinical course. A couple of months prior to the first visit, abnormal urinary findings started to emerge, followed by the elevation of serum creatinine. HCV in the circulation cleared and AST normalized within two weeks after the initiation of DAA therapy, and hematuria and proteinuria dramatically improved with subsequent improvement of kidney function despite sustained cryoglobulinemia and hypocomplementemia. Semi-quantified cryoglobulin value decreased in parallel with the serum levels of IgM and RF, following HCV eradication. ND not detected

Similar articles

Cited by

References

    1. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. doi: 10.1056/NEJM200107053450107. - DOI - PubMed
    1. Donadio JV, Offord PK. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis. 1989;14:445–451. doi: 10.1016/S0272-6386(89)80143-X. - DOI - PubMed
    1. Lopes E, Lopes LV, Silva AE. Mixedcryoglobulinemia and membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Ann Intern Med. 1996;125:781–782. doi: 10.7326/0003-4819-125-9-199611010-00030. - DOI - PubMed
    1. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219–227. doi: 10.1016/j.jhep.2014.04.004. - DOI - PubMed
    1. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont Mauviel M. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 Infection: a phase IIb trial. Gastroenterology. 2014;146:430–441. doi: 10.1053/j.gastro.2013.10.058. - DOI - PubMed

LinkOut - more resources